00:51 Sat 21 Nov 2020
Allergy Therapeutics - Grant of Awards under Long Term Incentive Plan
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Grant of Awards under Long Term Incentive Plan
Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, announces that, on
| Executive Director | Number of Conditional shares awarded |
| | 900,000 |
| Nick Wykeman | 450,000 |
The Awards have been granted in accordance with the LTIP rules and vesting is conditional on the satisfaction of two performance measures over a three-year period:
| Measure: | |
| Compounded annual earnings growth rate (EBITDA) pre R&D spend | 7.5% - 17.5%
|
| Compounded annual share price growth
| 15% - 40% |
Following the above share transactions, the Executive Directors hold the following:
| Director | Unvested LTIP Awards | Low cost Share Options | Interest in Ordinary Shares |
| | 3,600,000 | 211,250 | 3,325,000 |
| Nicolas Wykeman | 1,800,000 | 211,250 | 300,000 |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||||||||
| a)
| Name
|
| |||||||||
| 2
| Reason for the notification
| ||||||||||
| a)
| Position/status
|
| |||||||||
| b)
| Initial notification /Amendment
| Initial notification | |||||||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||||||||
| a)
| Name
| ALLERGY THERAPEUTICS PLC | |||||||||
| b)
| LEI
| LEIR97215202003301009534776 | |||||||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||||||||
| a)
| Description of the financial instrument, type of instrument
| Conditional award of shares under the Company's Long Term Incentive Plan
| |||||||||
| b) | Identification code | GB00B02LCQ05 | |||||||||
| c)
| Nature of the transaction
| Grant of Conditional Awards | |||||||||
| d)
| Price(s) and volume(s)
|
| |||||||||
| e)
| Aggregated information
| | |||||||||
| f)
| Date of the transaction
| | |||||||||
| g)
| Place of the transaction
| Outside a trading venue | |||||||||
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||||||||
| a)
| Name
| Nick Wykeman | |||||||||
| 2
| Reason for the notification
| ||||||||||
| a)
| Position/status
| Nick Wykeman - Chief Financial Officer and PDMR
| |||||||||
| b)
| Initial notification /Amendment
| Initial notification | |||||||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||||||||
| a)
| Name
| ALLERGY THERAPEUTICS PLC | |||||||||
| b)
| LEI
| LEIR97215202003301009534776 | |||||||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||||||||
| a)
| Description of the financial instrument, type of instrument
| Conditional award of shares under the Company's Long Term Incentive Plan
| |||||||||
| b) | Identification code | GB00B02LCQ05 | |||||||||
| c)
| Nature of the transaction
| Grant of Conditional Awards | |||||||||
| d)
| Price(s) and volume(s)
|
| |||||||||
| e)
| Aggregated information
| | |||||||||
| f)
| Date of the transaction
| | |||||||||
| g)
| Place of the transaction
| Outside a trading venue | |||||||||
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Consilium Strategic Communications
+44 20 3709 5700
Stern Investor Relations, Inc.
+1 212 362 1200
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines, that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
Formed in 1999 out of
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Quick facts: Allergy Therapeutics PLC
Price: -
Market: AIM
Market Cap: -
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HERE
